Abstract
Background
The ISARIC prospective multinational observational study is the largest cohort of hospitalized patients with COVID-19. We present relationships of age, sex, and nationality to presenting symptoms.
Methods
International, prospective observational study of 60,109 hospitalized symptomatic patients with laboratory-confirmed COVID-19 recruited from 43 countries between 30 January and 3 August 2020. Logistic regression was performed to evaluate relationships of age and sex to published COVID-19 case definitions and the most commonly reported symptoms.
Results
‘Typical’ symptoms of fever (69%), cough (68%) and shortness of breath (66%) were the most commonly reported. 92% of patients experienced at least one of these. Prevalence of typical symptoms was greatest in 30- to 60-year-olds (respectively 80%, 79%, 69%; at least one 95%). They were reported less frequently in children (≤18 years: 69%, 48%, 23%; 85%), older adults (≥70 years: 61%, 62%, 65%; 90%), and women (66%, 66%, 64%; 90%; vs men 71%, 70%, 67%; 93%). The most common atypical presentation under 60 years of age was nausea and vomiting, and over 60 years was confusion. Regression models showed significant differences in symptoms with sex, age and country.
Interpretation
Adults over 60 and children admitted to hospital with COVID-19 are less likely to present with typical symptoms. Nausea and vomiting are common atypical presentations under 30 years. Confusion is a frequent atypical presentation of COVID-19 in adults over 60 years. Women are less likely to experience typical symptoms than men.
Keywords: age group, COVID-19, SARS-CoV-2, sex, symptoms, diagnosis, case definition
Summary
Adults over 60 and children admitted to hospital with COVID-19 are less likely to have typical symptoms. Nausea and vomiting are common atypical presentations under 30 and confusion over 60. Women are less likely to experience typical symptoms than men.
Background
Despite the pandemic’s immense human cost, enormous economic toll, and extensive research response, the precise clinical characteristics of COVID-19 remain unclear [1]. At the start of the outbreak, COVID-19 was broadly characterised as a severe respiratory illness presenting with fever, cough and an atypical pneumonia [2–5]. Altered sense of taste and smell have since been found to be strongly associated with the disease [6, 7]. However, a review of 77 observational studies found substantial proportions of patients presenting with less typical symptoms [8].
The World Health Organization’s (WHO) clinical criteria for suspected COVID-19 is either a combination of acute fever and cough, or a combination of three or more of fever, cough, general weakness and fatigue, headache, myalgia, sore throat, coryza, dyspnoea, anorexia, nausea and vomiting, diarrhoea, and altered mental status [9]. Clinical criteria from the Centers for Disease Control and Prevention in the United States are at least two of fever, chills, rigors, myalgia, headache, sore throat, and new olfactory and taste disorder, or at least one of cough, shortness of breath or difficulty breathing [10]. Public Health England’s definition of possible COVID-19 is individuals with a new cough or temperature ≥37.8 °C, or a loss or change in sense of smell or taste [11]. The European Centre for Disease Prevention and Control clinical criteria are at least one of cough, fever, shortness of breath, or sudden onset anosmia, ageusia or dysgeusia [12].
Defining presenting symptoms of COVID-19 is further complicated by clinical experience suggesting that patients frequently present with atypical symptoms other than cough, fever and shortness of breath. This variation in the clinical characterisation of COVID-19 is problematic, as case definitions are used to guide clinical diagnosis, disease surveillance, and public health interventions.
The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC)/WHO Clinical Characterisation Protocol for Severe Emerging Infections is a standardized protocol for investigation of severe acute infections by pathogens of public health interest [13, 14]. Here we present an analysis of how symptoms of patients admitted to hospital with confirmed COVID-19 vary by age and sex.
Materials and methods
Study population, variables and measurement
Patients of any age admitted to hospital with suspected or confirmed COVID-19 were eligible for recruitment. This analysis was limited to patients admitted to hospital between 30 January and 3 August 2020 with symptomatic COVID-19, confirmed according to sites’ local laboratory methods. We excluded asymptomatic patients admitted to hospital solely for isolation, and patients admitted for other conditions who subsequently developed COVID-19 symptoms. Variables used in this analysis were age, sex at birth, symptoms, date of symptoms onset, SARS-CoV-2 confirmation, and country of recruitment. To allow proportions to be calculated with a reliable denominator, only symptoms specified on the case report forms were included in this analysis.
This observational study required no change to clinical management and permitted enrolment in other research. The study was approved by the World Health Organization Ethics Review Committee (RPC571 and RPC572). Local ethics approval was obtained for each participating country and site according to local requirements. Informed consent was obtained where required by local ethics committees. In many jurisdictions, ethics committees and public health authorities approved a waiver of consent.
Study design and setting
The ISARIC cohort is an international prospective observational study of patients admitted to hospital with COVID-19. Data were collected via electronic ‘Core’ and ‘Rapid’ ISARIC case report forms [15], and through aligned forms by ISARIC-4C Coronavirus Clinical Characterisation Consortium in the United Kingdom [16] and the COVID-19 Critical Care Consortium [17]. Investigators from 41 countries used Research Electronic Data Capture (REDCap, version 8.11.11, Vanderbilt University, Nashville, Tenn.) to contribute their data to a central database hosted by the University of Oxford. Additional data were submitted by investigators not using the University of Oxford REDCap database from Malaysia, Russia [18], and Spain. The primary objective of this analysis was to investigate how symptoms of patients admitted to hospital with confirmed COVID-19 vary by age and sex. Secondarily we investigated how sensitivity of clinical case definitions varied among these populations, and explored heterogeneity among countries.
Analysis
Data were converted to Study Data Tabulation Model (version 1.7, Clinical Data Interchange Standards Consortium, Austin, Tex.). We excluded patients who had all symptoms recorded as missing or unknown, and those with missing age, sex, country or onset date. Continuous variables were expressed as median with interquartile range (IQR), and categorical variables as counts with percentages. We tested for differences between female and male patients using Wilcoxon rank-sum tests for continuous variables and chi-square tests for categorical variables. We grouped patients into ten-year age bands (with a single group ≥90 years). We plotted most frequently reported symptoms by age group, presenting missing data as a third category. We collated symptoms according to four sets of clinical criteria, based on published criteria [9–12] modified to omit symptoms with large numbers of missing data:
Fever plus cough; or any three of fever, cough, fatigue, headache, myalgia, sore throat, rhinorrhoea, shortness of breath, nausea and vomiting, diarrhoea, and confusion;
Cough or shortness of breath; or any two of fever, myalgia, headache, and sore throat;
Cough or fever;
At least one of cough, fever, and shortness of breath.
Patients with missing details of cough, fever or shortness of breath were omitted from the composite groups; patients missing details of symptoms included in the lists of criteria 1 and 2 were classified according to their non-missing symptoms. We plotted proportions of patients meeting each set of criteria by ten-year age group with 95% confidence intervals (CI) calculated using the Clopper–Pearson method.
We used logistic regression to identify associations of age and sex with the twelve most prevalent symptoms. Age group and sex were included as fixed effects, with country as a random intercept. To display heterogeneity between countries on the same scale as the fixed effects, we plotted median odds ratios (MOR), which quantify variation between countries by comparing odds of an outcome between randomly chosen persons in different clusters who share covariates [19]. MORs are defined as a comparison of the greater propensity group to the lower propensity group, so lie in the range one to infinity [19].
79% of patients were recruited in a single country. As a sensitivity analysis, we repeated the analysis excluding patients from this country. Finally, we plotted age-stratified symptom frequencies for each country with at least 250 patients.
No minimum sample size was calculated. All significance tests were two-tailed. Analyses were performed using R (version 4.0.3, R Foundation for Statistical Computing, Vienna, Austria) with packages including binom, Epi, ggplot2, lme4, sjstats, tableone, and tidyverse.
Results
Data were available for 99,623 patients. We excluded 24,336 who did not have documented SARS-CoV-2 confirmation, 3290 with missing data, and 5794 who developed COVID-19 after admission to hospital. 6094 patients were admitted to hospital with asymptomatic COVID-19, with the greatest proportion in the age-band 10 to 20 years (46%). We included 60,109 patients (Figure 1), recruited from 394 sites in 43 countries (Supplementary Table 1), in this analysis. The median age of included patients was 70 years (IQR 54–82; Table 1). 929 (1.5%) were 18 years old or younger. Age distribution of patients varied among countries, between a median of 10 years in Poland, and 73 years in the United Kingdom (Supplementary Figure 1). 34,641 (58%) patients were male.
Figure 1. Flow of participants in this analysis.
4C, Coronavirus Clinical Characterisation Consortium; CCC, Critical Care Consortium; ISARIC, International Severe Acute Respiratory and emerging Infection Consortium; REDCap, Research Electronic Data Capture; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2.
Table 1.
Patient demographics
| Sex | ||||
|---|---|---|---|---|
| Variable* | Overall n = 60,109 |
Female n = 25,468 |
Male n = 34,641 |
P-value |
| Age (years): median [IQR] | 70 [54, 82] | 72 [55, 83] | 68 [54, 80] | <0.001 |
| Age bands (years) | <0.001 | |||
| 0–10 | 514 (0.9) | 221 (0.9) | 293 (0.8) | |
| 10–20 | 522 (0.9) | 221 (0.9) | 301 (0.9) | |
| 20–30 | 1972 (3.3) | 872 (3.4) | 1100 (3.2) | |
| 30–40 | 3209 (5.3) | 1450 (5.7) | 1759 (5.1) | |
| 40–50 | 5013 (8.3) | 1966 (7.7) | 3047 (8.8) | |
| 50–60 | 8581 (14.3) | 3280 (12.9) | 5301 (15.3) | |
| 60–70 | 9874 (16.4) | 3701 (14.5) | 6173 (17.8) | |
| 70–80 | 12333 (20.5) | 4916 (19.3) | 7417 (21.4) | |
| 80–90 | 13483 (22.4) | 6196 (24.3) | 7287 (21.0) | |
| >=90 | 4608 (7.7) | 2645 (10.4) | 1963 (5.7) | |
| Region† | <0.001 | |||
| East Asia & Pacific | 3252 (5.4) | 1117 (4.4) | 2135 (6.2) | |
| Europe & Central Asia | 55401 (92.2) | 23749 (93.3) | 31652 (91.4) | |
| Latin America & Caribbean | 162 (0.3) | 67 (0.3) | 95 (0.3) | |
| Middle East & North Africa | 91 (0.2) | 35 (0.1) | 56 (0.2) | |
| North America | 926 (1.5) | 413 (1.6) | 513 (1.5) | |
| South Asia | 267 (0.4) | 83 (0.3) | 184 (0.5) | |
| Sub-Saharan Africa | 10 (0.0) | 4 (0.0) | 6 (0.0) | |
| Country income classification† | <0.001 | |||
| High income | 54836 (91.2) | 23420 (92.0) | 31416 (90.7) | |
| Upper middle income | 5003 (8.3) | 1964 (7.7) | 3039 (8.8) | |
| Lower middle or low income | 270 (0.4) | 84 (0.3) | 185 (0.5) | |
IQR, interquartile range
Data are number (percent within columns) unless specified otherwise
According to World Bank classification [20]
The most frequently reported symptoms were fever, cough and shortness of breath (Table 2). These symptoms were each more prevalent in male patients, whereas less typical symptoms such as confusion, nausea and vomiting, diarrhoea, chest pain, headache and abdominal pain were more prevalent in female patients. The greatest sex-related difference was for nausea and vomiting, reported by 23% of female patients but only 16% of male patients. For most symptoms, the greatest prevalence was reported in adults aged between 30 and 60 years, decreasing toward extremities of age (Figure 2). Frequency of confusion increased with age. Large numbers of patients had missing data for anorexia, severe dehydration, altered sense of taste and smell, and inability to walk as these were not included on all case report forms. Altered sense of taste and smell, which we had excluded from the composite criteria, were experienced by only 7.4% and 6.2% respectively of patients with non-missing data.
Table 2.
Symptoms at presentation to hospital with COVID-19
| Sex | |||||
|---|---|---|---|---|---|
| Variable* | Overall n = 60,109 |
Female n = 25,468 |
Male n = 34,641 |
P-value | Missing data† |
| Fever | 41067 (68.7) | 16649 (65.7) | 24418 (70.8) | <0.001 | 291 (0.5) |
| Cough | 40898 (68.5) | 16683 (65.9) | 24215 (70.4) | <0.001 | 401 (0.7) |
| Shortness of breath | 37577 (65.8) | 15450 (64.0) | 22127 (67.2) | <0.001 | 3024 (5.0) |
| Fatigue | 23319 (46.4) | 9889 (46.3) | 13430 (46.5) | 0.622 | 9893 (16.5) |
| Confusion | 13732 (27.3) | 6108 (28.2) | 7624 (26.5) | <0.001 | 9730 (16.2) |
| Muscle pains | 9472 (20.1) | 3952 (19.8) | 5520 (20.3) | 0.137 | 12980 (21.6) |
| Diarrhoea | 10061 (19.1) | 4565 (20.4) | 5496 (18.2) | <0.001 | 7544 (12.6) |
| Nausea and vomiting | 9891 (18.8) | 5099 (22.8) | 4792 (15.8) | <0.001 | 7464 (12.4) |
| Anorexia | 613 (15.7) | 243 (14.3) | 370 (16.8) | 0.038 | 56202 (93.5) |
| Severe dehydration | 3451 (14.8) | 1562 (15.4) | 1889 (14.3) | 0.027 | 36756 (61.1) |
| Chest pain | 6953 (13.6) | 3084 (14.2) | 3869 (13.1) | 0.001 | 8953 (14.9) |
| Headache | 6154 (13.0) | 2830 (14.1) | 3324 (12.2) | <0.001 | 12796 (21.3) |
| Sore throat | 4880 (10.5) | 2135 (10.8) | 2745 (10.3) | 0.097 | 13836 (23.0) |
| Abdominal pain | 5305 (10.4) | 2597 (12.0) | 2708 (9.2) | <0.001 | 9015 (15.0) |
| Wheeze | 3845 (7.9) | 1790 (8.6) | 2055 (7.4) | <0.001 | 11390 (18.9) |
| Altered sense of taste | 2011 (7.4) | 924 (7.8) | 1087 (7.1) | 0.023 | 32830 (54.6) |
| Joint pains | 3229 (7.1) | 1459 (7.5) | 1770 (6.8) | 0.002 | 14587 (24.3) |
| Altered sense of smell | 1733 (6.2) | 819 (6.7) | 914 (5.7) | 0.001 | 31969 (53.2) |
| Rhinorrhoea | 2382 (5.2) | 1041 (5.3) | 1341 (5.1) | 0.264 | 14403 (24.0) |
| Unable to walk | 220 (5.0) | 83 (4.4) | 137 (5.4) | 0.141 | 55668 (92.6) |
| Skin ulcer | 978 (2.3) | 489 (2.7) | 489 (2.1) | <0.001 | 18486 (30.8) |
| Haemorrhage | 993 (2.0) | 429 (2.0) | 564 (2.0) | 0.695 | 9902 (16.5) |
| Lower chest wall | |||||
| indrawing | 688 (1.6) | 235 (1.3) | 453 (1.9) | <0.001 | 17887 (29.8) |
| Seizure | 775 (1.6) | 352 (1.7) | 423 (1.5) | 0.169 | 12055 (20.1) |
| Rash | 694 (1.4) | 287 (1.4) | 407 (1.5) | 0.555 | 11400 (19.0) |
| Lymphadenopathy | 307 (0.7) | 147 (0.8) | 160 (0.6) | 0.099 | 15267 (25.4) |
| Conjunctivitis | 251 (0.5) | 111 (0.5) | 140 (0.5) | 0.642 | 12491 (20.8) |
| Ear pain | 201 (0.5) | 107 (0.6) | 94 (0.4) | 0.003 | 19036 (31.7) |
| Composite categories | 3446 (5.7)‡ | ||||
| Fever and cough; or at least three of fever, cough, fatigue, headache, muscle pains, sore throat, rhinorrhoea, shortness of breath, nausea and vomiting, diarrhoea, and confusion | |||||
| 40911 (72.2) | 17014 (71.0) | 23897 (73.1) | <0.001 | ||
| Cough or shortness of breath; or at least two of fever, muscle pains, headache, or sore throat | |||||
| 48464 (85.5) | 20103 (83.9) | 28361 (86.7) | <0.001 | ||
| Cough or fever | 48494 (85.6) | 19973 (83.3) | 28521 (87.2) | <0.001 | |
| At least one of cough, fever or shortness of breath | |||||
| 52041 (91.8) | 21607 (90.2) | 30434 (93.1) | <0.001 | ||
Data are number (percent of patients with non-missing data within columns) unless specified otherwise
Number (percent of all patients)
Patients missing any of cough, fever or shortness of breath are omitted from the composite categories
Figure 2. Age-specific prevalence of symptoms at hospital admission.
Dark blue bars show symptom present, maroon bars show symptom absent, pale grey bars show missing data.
Data on cough, fever or shortness of breath were missing for 3446 patients. The composite clinical criteria were calculated for the remaining 56,663 patients. Each set of criteria was met by a greater proportion of patients aged 30 to 60 years than those toward either extreme of age (Figure 3). The criteria based on WHO’s clinical criteria [9] (fever plus cough; or any three of fever, cough, fatigue, headache, myalgia, sore throat, rhinorrhoea, shortness of breath, nausea and vomiting, diarrhoea, and confusion) were met by 40,911 (72%) patients, but only 51% of those aged 18 years and under, and 67% of those aged 70 years or over. The most sensitive criteria were at least one of cough, fever and shortness of breath, met by 52,041 (92%) participants. These criteria were met by 85% aged 18 years and under, and 90% of those aged 70 years or over. Each set of criteria were met by a greater proportion of male than female patients (Table 2).
Figure 3. Proportions meeting clinical criteria at hospital admission stratified by 10-year age band.
Black boxes show the proportion of individuals, with error bars showing 95% confidence intervals calculated using the Clopper–Pearson method. The size of each box is inversely proportional to the variance, so larger boxes indicate greater certainty. Grey boxes with 95% confidence intervals show the proportions in the sensitivity analysis excluding patients recruited in the United Kingdom. In panel A, the three symptoms are from the list of fever, cough, fatigue, headache, myalgia, sore throat, rhinorrhoea, shortness of breath, nausea and vomiting, diarrhoea, and confusion; in panel B the two symptoms are from the list fever, myalgia, headache, and sore throat. Patients with missing data for cough, fever or shortness of breath are excluded from all four plots.
For the 4622 patients whose symptoms did not meet any assessed case definitions, the most frequent symptom was confusion (47%; Table 3). This increased with age to 66% of those aged 90 years or older. Nausea and vomiting, and abdominal pain were the most common symptoms for people less than 60 years old who had not met any of the case definitions.
Table 3.
Symptoms reported for patients meeting none of the clinical case definitions
| Age group (years) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Symptom* | Overall n = 4622 |
0- n = 44 |
10- n = 100 |
20- n = 269 |
30- n = 256 |
40- n = 217 |
50- n = 309 |
60- n = 484 |
70- n = 922 |
80- n = 1406 |
90- n = 615 |
Missing data |
| Confusion | 1917 (46.9) | 4 (9.8) | 2 (4.2) | 7 (6.2) | 9 (5.8) | 23 (14.1) | 57 (21.3) | 155 (35.1) | 474 (52.8) | 785 (57.7) | 401 (66.4) | 531 (11.5) |
| Fatigue | 1245 (29.1) | 9 (23.1) | 10 (10.3) | 30 (11.3) | 37 (15.2) | 42 (20.7) | 83 (28.1) | 148 (33.2) | 284 (33.3) | 444 (34.4) | 158 (28.6) | 340 (7.4) |
| Severe dehydration | 472 (22.6) | 1 (5.0) | 1 (4.3) | 4 (8.3) | 2 (2.9) | 7 (11.3) | 18 (13.1) | 40 (18.0) | 110 (24.8) | 201 (27.1) | 88 (27.6) | 2535 (54.8) |
| Nausea and vomiting | 995 (22.2) | 19 (44.2) | 24 (24.0) | 44 (16.4) | 59 (23.4) | 77 (36.0) | 94 (31.2) | 127 (27.1) | 210 (23.4) | 245 (18.3) | 96 (16.2) | 145 (3.1) |
| Abdominal pain | 812 (18.5) | 9 (22.5) | 22 (22.4) | 52 (19.5) | 67 (26.6) | 54 (25.8) | 80 (27.0) | 107 (23.1) | 173 (19.6) | 184 (13.9) | 64 (11.2) | 223 (4.8) |
| Diarrhoea | 612 (13.8) | 8 (19.0) | 6 (6.1) | 26 (9.7) | 25 (10.0) | 31 (14.8) | 46 (15.5) | 94 (20.3) | 136 (15.2) | 177 (13.4) | 63 (10.9) | 201 (4.3) |
| Headache | 347 (8.3) | 2 (6.1) | 13 (13.4) | 48 (18.4) | 39 (16.0) | 47 (23.2) | 32 (11.0) | 45 (10.3) | 52 (6.3) | 47 (3.8) | 22 (4.1) | 454 (9.8) |
| Muscle pains | 301 (7.3) | 4 (11.8) | 5 (5.2) | 19 (7.2) | 28 (11.5) | 24 (12.1) | 27 (9.4) | 39 (9.0) | 54 (6.6) | 65 (5.3) | 36 (6.8) | 482 (10.4) |
| Joint pains | 293 (7.1) | 3 (9.1) | 4 (4.2) | 9 (3.4) | 8 (3.3) | 13 (6.5) | 14 (4.9) | 27 (6.2) | 49 (6.0) | 109 (8.8) | 57 (10.7) | 473 (10.2) |
| Chest pain | 299 (6.8) | 0 (0.0) | 1 (1.0) | 12 (4.5) | 15 (6.0) | 21 (9.8) | 44 (14.6) | 49 (10.6) | 51 (5.8) | 79 (6.0) | 27 (4.7) | 209 (4.5) |
| Sore throat | 277 (6.7) | 4 (11.1) | 24 (25.0) | 83 (31.7) | 62 (25.1) | 39 (19.3) | 16 (5.5) | 18 (4.1) | 17 (2.1) | 9 (0.7) | 5 (1.0) | 460 (10.0) |
| Haemorrhage | 233 (5.5) | 0 (0.0) | 1 (1.1) | 5 (2.1) | 10 (4.3) | 12 (6.0) | 14 (4.8) | 22 (4.9) | 45 (5.2) | 84 (6.5) | 40 (7.0) | 347 (7.5) |
| Altered sense of smell | 149 (4.9) | 1 (4.0) | 20 (24.1) | 48 (22.7) | 30 (16.0) | 17 (11.4) | 11 (5.1) | 9 (2.8) | 4 (0.7) | 9 (1.0) | 0 (0.0) | 1584 (34.3) |
| Rhinorrhoea | 188 (4.5) | 3 (7.5) | 28 (29.2) | 58 (22.1) | 43 (17.6) | 23 (11.4) | 14 (4.8) | 7 (1.6) | 6 (0.7) | 2 (0.2) | 4 (0.7) | 476 (10.3) |
| Skin ulcer | 153 (4.2) | 1 (3.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (1.5) | 9 (3.7) | 13 (3.3) | 43 (5.3) | 51 (4.1) | 34 (6.2) | 982 (21.2) |
| Seizure | 152 (3.8) | 5 (11.6) | 3 (6.2) | 3 (2.7) | 6 (3.9) | 11 (6.7) | 16 (6.1) | 22 (5.1) | 34 (3.9) | 39 (3.0) | 13 (2.3) | 659 (14.3) |
| Altered sense of taste | 101 (3.3) | 1 (4.5) | 10 (12.0) | 27 (13.0) | 15 (8.1) | 10 (6.8) | 3 (1.4) | 7 (2.2) | 11 (2.0) | 13 (1.5) | 4 (1.0) | 1602 (34.7) |
| Rash | 78 (1.8) | 5 (11.6) | 3 (3.0) | 2 (0.8) | 1 (0.4) | 4 (2.0) | 5 (1.7) | 17 (3.8) | 18 (2.2) | 15 (1.2) | 8 (1.5) | 384 (8.3) |
| Wheeze | 53 (1.2) | 0 (0.0) | 0 (0.0) | 1 (0.4) | 1 (0.4) | 0 (0.0) | 3 (1.0) | 6 (1.3) | 8 (0.9) | 22 (1.7) | 12 (2.1) | 296 (6.4) |
Data are number (percent of patients with non-missing data within columns). Symptoms experienced by <25 individuals are omitted.
In the logistic regression models (Figure 4), similar associations between age and symptoms were seen after adjustment for sex and relationship of onset to admission date as in the unadjusted bar charts. Confusion increased with age. Nausea and vomiting, headache, abdominal pain, and sore throat were each more frequent in younger age groups, decreasing with age. The 95% CI for sex excluded one for most symptoms, but for most the point estimate was close to one. Male patients had greater odds of fever, cough and shortness of breath, and lower odds of gastrointestinal symptoms of nausea and vomiting, diarrhoea, abdominal pain, chest pain, headache and sore throat. The median odds ratio for heterogeneity between countries was greater than the relationship with sex in all symptoms. It was of similar magnitude to the relationship with age for most symptoms. For each symptom, heterogeneity between countries was of a similar magnitude to the effect of age, and a greater magnitude than sex.
Figure 4. Odds of symptoms among patients admitted to hospital with COVID-19, stratified by age and sex.
Each plot is the result of a logistic regression with a symptom as an outcome. Fixed effects of age in ten-year bands (baseline group 50–60 years) and sex are shown in black boxes with 95% confidence intervals. The size of each square is inversely proportional to the variance of the log odds ratio, so larger boxes indicate greater certainty. Clustering by country is included as a random intercept and heterogeneity is depicted by circles showing the median odds ratio.
47,280 (79%) patients were included from the United Kingdom. Excluding these patients, the patterns of symptoms were similar to the main analysis (Supplementary Figure 2). The peak prevalence of fever, cough and shortness of breath was in 70- to 80-year-olds, and fatigue increased with age. Below the age of 50 years, the clinical case definitions tended to be less sensitive in the analysis excluding the United Kingdom than in the analysis including it; above the age of 70 years each tended to be more sensitive (grey lines in Figure 3). Within countries, the baseline prevalence of each symptom varied but patterns within countries were broadly similar to the overall results (Supplementary figures 3–14).
Discussion
The ISARIC prospective multinational cohort study is the largest cohort of patients admitted to hospital with COVID-19. In this report, we confirmed a relationship between patients’ symptoms and their age and sex. The ‘typical’ COVID-19 symptoms occur most frequently in adults aged 30 to 60 years. Commonly used case definitions in use can miss up to half of children and a third of adults over 70 years who are admitted to hospital with COVID-19.
Our results support the findings of smaller cohort studies that atypical symptoms are more common in older adults [21], and correlate with similar findings of atypical presentations for pneumonia, bacteraemia and coronary artery disease [22, 23]. A lower prevalence of symptoms in children and young people has previously been suggested [24, 25], but this is the first large international cohort to collect data prospectively from both adults and children.
Separate analyses of the ISARIC-4C data have identified fever, cough and shortness of breath as frequently co-occurring clusters of symptoms [26, 27]. In children, the next most frequent cluster consisted of systemic, enteric and mucocutaneous symptoms [26]. For adults, other clusters consisted of non-specific viral symptoms, gastrointestinal symptoms, upper respiratory symptoms, neurological symptoms, and symptoms of bronchospasm [27]. Those data were included in this global dataset so the results of these analyses are not independent of our results.
We found that differences in symptoms by sex were statistically significant but generally of smaller magnitude. Typical symptoms of fever, cough and shortness of breath were more common in men than in women; all other symptoms were equal or more common in female patients. A cohort of non-hospitalized patients with COVID-19 in Poland found greater differences in symptoms of lack of appetite (55% of women, 36% of men) and taste disorder (53% women, 40% men) [28]. We are unable to determine from our data whether these differences reflect differences in health-seeking behaviour between men and women, or a biological difference in their response to the infection. Elaboration of this difference should be a goal of future research.
Our results suggest considerable heterogeneity among countries. We have not attempted to elicit reasons for heterogeneity. Potential reasons include cultural idiosyncrasies in reporting symptoms, and hospitals’ criteria for admission and testing. It might also reflect differences in local patient recruitment. Researchers in some countries may be unwilling to recruit confused patients due to requirements for consent, whereas in others the requirement for consent has been waived or could be obtained from a proxy.
We explored the effect of using the country of recruitment as a random effect in regression models and by repeating the analysis excluding the largest country. Each analysis suggested an underlying pattern of lower frequencies of typical symptoms in children and older adults. Therefore, although the prevalence of each symptom reported in this study may not apply to all settings, we have evidence to support the possibility of age-dependent differences internationally.
The size of this cohort is a strength. To our knowledge, it is the largest cohort of hospitalized COVID-19 patients in the world. However, the study has several limitations. Firstly, almost 80% of patients were recruited in a single country. Moreover, less than 1% of patients were recruited from low- or lower-middle-income countries. Secondly, the cohort overwhelmingly includes older adults, with only 1.8% of the cohort aged 18 years or younger. Thirdly, our analysis includes only patients who were hospitalized with COVID-19 and who had a laboratory-confirmed diagnosis. This patient population is more likely to be severely unwell and more likely to exhibit symptoms typically associated with COVID-19 than people who were managed in the community or whose disease has not been recognized. Accordingly, the reporting of ‘typical’ COVID-19 symptoms in this cohort is likely to be an overestimate of the population prevalence. Symptoms are subjective and cannot be externally verified. Some differences for children may reflect that symptoms could only be recorded if a caregiver recognised the symptom or the child had the appropriate vocabulary to describe it. Similarly, some symptoms may be under-reported in elderly patients if there are difficulties in communication, for example due to delirium. As such, the generalizability of estimates of our symptom prevalence is limited. Similarly, there is a shortage of studies conducted outside of high-income countries: a recent scoping review of clinical characteristics of COVID-19 identified no large cohorts in non-high-income countries except China [8].
The absence of a control group of patients without COVID-19 in this dataset prevented estimation of specificity or positive and negative predictive values. We are therefore prevented from advocating changes to clinical case definitions, as such decisions inevitably require a balance of false-positive and false-negative rates. However, given the prevalence of atypical symptoms in our cohort, we can confidently suggest that reliance on clinical case definitions may result in missing cases of COVID-19, especially among children and older adults. Non-healthcare professionals making decisions regarding isolation may be especially vulnerable to missing cases of COVID-19 by adhering to a clinical case definition too strictly.
The reported prevalence of COVID-19 may also rely on a strict interpretation of case definitions. In settings where comprehensive contact tracing is planned, or there is easy access to microbiological testing, a highly sensitive case definition is desirable. However, where decisions are based on clinical diagnoses, it is important to recognize other pathogens that can cause similar constellations of symptoms. The addition of symptoms such as confusion or gastrointestinal symptoms to the COVID-19 case definition could increase sensitivity, but at the cost of reduced specificity. Changes in the senses of taste and smell have recently been added to case definitions. Our data suggest that these criteria would detect only a small proportion of patients admitted to hospital with COVID-19 who were omitted by other definitions.
These results highlight the need to consider COVID-19 even if individuals do not display typical symptoms of the disease. This is especially the case in children and older adults. Given that our results are likely to overestimate the sensitivity of the clinical criteria currently used to identify patients for testing, our results suggest a lower limit to the proportion of people in the community with COVID-19 who would not be identified. Addition of confusion as a symptom would increase the sensitivity of case definitions for older adults; and inclusion of nausea and vomiting or abdominal pain would increase sensitivity for children and young adults. The high proportion of asymptomatic patients identified in patients aged 10 to 20 years suggests that universal screening in these ages could be beneficial when there is widespread community circulation of COVID-19. Ongoing data collection outside high-income countries is needed to establish whether alternative case definitions are needed in different settings. Work is also ongoing to determine whether some constellations of symptoms are associated with better or poorer outcomes than others.
Supplementary Material
Figure 5. Age- and sex- specific odds of meeting clinical definitions among patients admitted to hospital with COVID-19, stratified by age and sex.
Each plot is the result of a logistic regression with a composite group of symptoms as an outcome. Fixed effects of age in ten-year bands (baseline group 50–60 years) and sex are shown in black boxes with 95% confidence intervals. The size of each square is inversely proportional to the variance of the log odds ratio, so larger boxes indicate greater certainty. Clustering by country is included as a random intercept and heterogeneity is depicted by circles showing the median odds ratio. In panel A, the three symptoms are from the list of fever, cough, fatigue, headache, myalgia, sore throat, rhinorrhoea, shortness of breath, nausea and vomiting, diarrhoea, and confusion; in panel B the two symptoms are from the list fever, myalgia, headache, and sore throat. Patients with missing data for cough, fever or shortness of breath are excluded from all four plots.
Acknowledgements
We are extremely grateful to the frontline clinical and research staff and volunteers, who collected this data in challenging circumstances, and the generosity of the patients and their families for their individual contributions in these difficult times. This work uses data provided by patients and collected by the health institutions and authorities in each country. In the UK, this study involves the National Health Service as part of their care and support #DataSavesLives. We also acknowledge the support of Jeremy J Farrar, Nahoko Shindo, Devika Dixit, Nipunie Rajapakse, Andrew Davison, David Barr, Lyndsey Castle, Martha Buckley, Debbie Malden, Katherine Newell, Kwame O’Neill, Emmanuelle Denis, Claire Petersen, Scott Mullaney, Sue MacFarlane, Nicole Maziere, Julien Martinez, Oslem Dincarslan, Annette Lake and the Irish Critical Care Trials Group. We appreciate the strong collaboration of the WHO Clinical Data Platform Team, including Silvia Bertagnolio, Soe Soe Thwin, and Janet Diaz.
Funding
This work was supported by the Department for International Development and Wellcome Trust [215091/Z/18/Z]; the Bill and Melinda Gates Foundation [OPP1209135]. Country-specific support was provided by the Canadian Institutes of Health Research Coronavirus Rapid Research Funding Opportunity [OV2170359]; the Health Research Board Ireland [CTN Award 2014-012]; National Institute for Health Research (NIHR) [award CO-CIN-01]; the Medical Research Council (MRC) [grant MC_PC_19059]; the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford [award 200907]; NIHR HPRU in Respiratory Infections at Imperial College London with PHE [award 200927]; Liverpool Experimental Cancer Medicine Centre [grant reference C18616/A25153]; NIHR Biomedical Research Centre at Imperial College London [IS-BRC-1215-20013]; EU Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) [FP7 project 602525]; National Institutes of Health (NIH) [UL1TR002240]; and NIHR Clinical Research Network infrastructure support. We acknowledge the generous support of all ISARIC Partners who have contributed data and expertise to this analysis, with or without dedicated funding. The views expressed are those of the authors and not necessarily those of the funders or institutions listed above.
Footnotes
Competing interests
M. Cheng declares grants from McGill Interdisciplinary Initiative in Infection and Immunity, and Canadian Institutes of Health Research; and personal fees from GEn1E Lifesciences (as a member of the scientific advisory board) and nplex biosciences (as a member of the scientific advisory board); M. Cummings and M. O’Donnell participated as investigators for completed and ongoing clinical trials evaluating the efficacy and safety of remdesivir (sponsored by Gilead Sciences) and convalescent plasma (sponsored by Amazon), in hospitalized patients with COVID-19 – support for this work is paid to Columbia University; J. C. Holter declared grants from Research Council of Norway [grant 312780], and Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner, during the conduct of the study; A.Kimmoun declared personal fees (payment for lectures) from Baxter, Aguettant, Aspen; D. Kumar declared grants and personal fees from Roche, GSK and Merck, and personal fees from Pfizer and Sanofi; F.X. Lescure declared personal fees (payment for lectures) from Gilead, MSD; and travel/accommodation/meeting expenses from Astellas, Eumedica, MSD; A. Pesenti declared personal fees from Maquet, Novalung/Xenios, Baxter, and Boehringer Ingelheim; S. Shrapnel reported grants from Prince Charles Hospital Foundation during the conduct of the study, and concurrently performed data analytics for the COVID-19 Critical Care Consortium; R. Tedder reports grants from MRC/UKRI during the conduct of the study, and has a patent United Kingdom Patent Application No. 2014047.1 “SARS-CoV-2 antibody detection assay” issued; J. Troost declared personal fees from General Electric and Procter and Gamble.
Ethics approval
This observational study required no change to clinical management and permitted enrolment in other research. The study was approved by the World Health Organization Ethics Review Committee (RPC571 and RPC572). Local ethics approval was obtained for each participating country and site according to local requirements.
Consent to participate
Informed consent was sought where required by local ethics committees. In many jurisdictions, ethics committees and public health authorities approved a waiver of consent to collect anonymised clinical data in the context of this public health emergency.
Availability of data and materials
We welcome applications for UK data through the ISARIC 4C Independent Data and Material Access Committee (https://isaric4c.net). Requests for access to non-UK data can be sent to covid19@iddo.org.
References
- 1.Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, Spijker R, Hooft L, Emperador D, Dittrich S, Domen J, Horn SRA, Van den Bruel A. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev 2020: 7(7): Cd013665. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020: 382(18): 1708–1720. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020: 395(10223): 497–506. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Liang WH, Guan WJ, Li CC, Li YM, Liang HR, Zhao Y, Liu XQ, Sang L, Chen RC, Tang CL, Wang T, Wang W, He QH, Chen ZS, Wong SS, Zanin M, Liu J, Xu X, Huang J, Li JF, Ou LM, Cheng B, Xiong S, Xie ZH, Ni ZY, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. Eur Respir J 2020: 55(6): 2000562. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Wang G, Chen W, Jin X, Chen YP. Description of COVID-19 cases along with the measures taken on prevention and control in Zhejiang, China. J Med Virol 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, Rusconi S, Gervasoni C, Ridolfo AL, Rizzardini G, Antinori S, Galli M. Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: A cross-sectional study. Clin Infect Dis 2020: 71(15): 889–890. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms. Int Forum Allergy Rhinol 2020: 10(7): 806–813. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Manoharan L, Cattrall JWS, Harris C, Newell K, Thomson B, Pritchard MG, Bannister PG, Sigfrid L, Solomon T, Horby PW, Carson G, Olliaro PL. Early clinical characteristics of Covid-19: scoping review. MedRxiv 2020: 2020 07.31.20165738 [Preprint]. August 4, 2020 [cited 7 August 2020]. . [Google Scholar]
- 9.World Health Organization. WHO COVID-19: Case definitions [WHO/2019-nCoV/Surveillance_Case_Definition/2020.1]. Geneva, Switzerland: World Health Organization; 2020. [Google Scholar]
- 10.Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) 2020 interim case definition. 2020. [cited 2020 9 November]; Available from: https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/
- 11.Public Health England. COVID19: investigation and initial clinical management of possible cases. 2020. [cited 2020 9 November]; Available from: https://www.gov.uk/government/publications/wuhan-novel-coronavirus-initial-investigation-of-possible-cases/investigation-and-initial-clinical-management-of-possible-cases-of-wuhan-novel-coronavirus-wn-cov-infection
- 12.European Centre for Disease Prevention and Control. Case definition for coronavirus disease 2019 (COVID-19), as of 29 May 2020. 2020. [cited 2020 9 November]; Available from: https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition
- 13.International Severe Acute Respiratory and Emerging Infection Consortium, World Health Organization. ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections, version 3.2: ISARIC; 2020. [Google Scholar]
- 14.ISARIC clinical characterisation group. Global outbreak research: harmony not hegemony. Lancet Infect Dis 2020: 20(7): 770–772. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.International Severe Acute Respiratory and Emerging Infection Consortium. COVID-19 CRF. 2020. [cited 21 August 2020]; Available from: https://isaric.org/research/covid-19-clinical-research-resources/covid-19-crf/
- 16.ISARIC 4C. ISARIC 4C protocols. 2020. [cited 26 August 2020]; Available from: https://isaric4c.net/protocols/
- 17.COVID-19 Critical Care Consortium. COVID-19 Critical Care Consortium Trial Documents. 2020. [cited 26 August 2020]; Available from: https://www.elso.org/COVID19/ECMOCARD.aspx
- 18.Munblit D, Nekliudov NA, Bugaeva P, Blyuss O, Kislova M, Listovskaya E, Gamirova A, Shikhaleva A, Belyaev V, Timashev P, Warner JO, Comberiati P, Apfelbacher C, Bezrukov E, Politov ME, Yavorovskiy A, Bulanova E, Tsareva N, Avdeev S, Kapustina VA, Pigolkin YI, Dankwa EA, Kartsonaki C, Pritchard MG, Victor F, Svistunov AA, Butnaru D, Glybochko P. StopCOVID cohort: An observational study of 3,480 patients admitted to the Sechenov University hospital network in Moscow city for suspected COVID-19 infection. Clin Infect Dis 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Larsen K, Merlo J. Appropriate assessment of neighborhood effects on individual health: integrating random and fixed effects in multilevel logistic regression. Am J Epidemiol 2005: 161(1): 81–8. [DOI] [PubMed] [Google Scholar]
- 20.World Bank. World Bank country and lending groups. 2020. [cited; Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups
- 21.Lauretani F, Ravazzoni G, Roberti MF, Longobucco Y, Adorni E, Grossi M, De Iorio A, La Porta U, Fazio C, Gallini E, Federici R, Salvi M, Ciarrocchi E, Rossi F, Bergamin M, Bussolati G, Grieco I, Broccoli F, Zucchini I, Ielo G, Morganti S, Artoni A, Arisi A, Tagliaferri S, Maggio M. Assessment and treatment of older individuals with COVID 19 multi-system disease: Clinical and ethical implications. Acta Biomed 2020: 91(2): 150–168. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Jung YJ, Yoon JL, Kim HS, Lee AY, Kim MY, Cho JJ. Atypical clinical presentation of geriatric syndrome in elderly patients with pneumonia or coronary artery disease. Ann Geriatr Med Res 2018: 21(4): 158–163. [Google Scholar]
- 23.Wester AL, Dunlop O, Melby KK, Dahle UR, Wyller TB. Age-related differences in symptoms, diagnosis and prognosis of bacteremia. BMC Infect Dis 2013: 13: 346. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, Zhang W, Wang Y, Bao S, Li Y, Wu C, Liu H, Liu D, Shao J, Peng X, Yang Y, Liu Z, Xiang Y, Zhang F, Silva RM, Pinkerton KE, Shen K, Xiao H, Xu S, Wong GWK. SARS-CoV-2 Infection in Children. N Engl J Med 2020: 382(17): 1663–1665. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 2020: 109: 1088–1095. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Swann OV, Holden KA, Turtle L, Pollock L, Fairfield CJ, Drake TM, Seth S, Egan C, Hardwick HE, Halpin S, Girvan M, Donohue C, Pritchard M, Patel LB, Ladhani S, Sigfrid L, Sinha IP, Olliaro PL, Nguyen-Van-Tam JS, Horby PW, Merson L, Carson G, Dunning J, Openshaw PJM, Baillie JK, Harrison EM, Docherty AB, Semple MG. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ 2020: 370: m3249. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Millar JE, Neyton L, Seth S, Dunning J, Merson L, Murthy S, Russell CD, Keating S, Swets M, Sudre CH, Spector TD, Ourselin S, Steves CJ, Wolf J, Docherty AB, Harrison EM, Openshaw PJ, Semple MG, Baillie JK. Robust, reproducible clinical patterns in hospitalised patients with COVID-19. MedRxiv 2020: 2020.08.14.20168088 [Preprint]. August 16, 2020 [cited 2 September 2020]. [Google Scholar]
- 28.Sierpiński R, Pinkas J, Jankowski M, Zgliczyński WS, Wierzba W, Gujski M, Szumowski Ł. Sex differences in the frequency of gastrointestinal symptoms and olfactory or taste disorders in 1942 nonhospitalized patients with coronavirus disease 2019 (COVID-19). Pol Arch Intern Med 2020: 130(6): 501–505. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.